97. Ulcerative colitis Clinical trials / Disease details
Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05119140 (ClinicalTrials.gov) | February 2022 | 20/10/2021 | HCQ for Non Europeans With Mild to Severe UC | Administration of Hydroxychloroquine (Plaquenil) to Individuals of Non-European Ancestry for the Treatment of Mild to Severe Ulcerative Colitis. | Ulcerative Colitis (Disorder) | Drug: Hydroxychloroquine;Drug: Mesalamine | Icahn School of Medicine at Mount Sinai | Crohn's and Colitis Foundation | Recruiting | 18 Years | N/A | All | 20 | Phase 1/Phase 2 | United States |